BRCA1 mutation carriers have an increased susceptibility to breast and ovarian cancer. Excision of exon 11 of Brca1 in the mouse, using a conditional knockout (Cre-loxP) approach, results in mammary tumor formation after long latency. To characterize the genomic instability observed in these tumors, to establish a comparative map of chromosomal imbalances and to contribute to the validation of this mouse model of breast cancer, we have characterized chromosomal imbalances and aberrations using comparative genomic hybridization (CGH), and spectral karyotyping (SKY). We found that all tumors exhibit chromosome instability as evidenced by structural chromosomal aberrations and aneuploidy, yet they display a pattern of chromosomal gain and loss that is similar to the pattern in human breast carcinomas. Of note, nine of 15 tumors exhibited a gain of distal chromosome 11, a region that is orthologous to human chromosome 17q11-qter, the mapping position of Erbb2. However, our analysis suggests that genes distal to Erbb2 are the main targets of amplification. Four of the tumors also exhibited a copy number loss of proximal chromosome 11 (11A-B), a region orthologous to human 17p. In eight of the tumors we observed whole or partial gain of chromosome 15 centering on 15D2-D3 (orthologous to human chromosome 8q24), the map location of the c-Myc gene, and six of the tumors exhibited copy number loss of whole or partial chromosome 14, including 14D3, the map location of Rb1. We conclude that despite the tremendous shuffling of chromosomes during the course of mammalian evolution, the pattern of genomic imbalances is conserved between BRCA1-associated mammary gland tumors in mice and humans. Western blot analysis showed that while p53 is absent or mutated in some tumors, at least two tumors revealed wild-type protein, suggesting that other genetic events may lead to tumorigenesis. Similar to
Introduction
Loss of one copy of the BRCA1 tumor suppressor gene is responsible for increased susceptibility to familial breast and ovarian cancer. Functional analyses of BRCA1 revealed its involvement in DNA damageinduced repair and regulation of transcription (Deng and Scott, 2000) . BRCA1 co-localizes with the RAD50/MRE 11/NBS1 repair complex in nuclear foci (Zhong et al., 1999) , and associates with the SWI/SNF chromatin-remodeling complex (Bochar et al., 2000) . This is consistent with the hypothesis that the genomic instability observed in Brca1-null cells is due to defects in homologous recombination. Thus, failure to repair double-strand breaks results in an accumulation of genetic damage in Brca1-null cells. If this damage affects gatekeeper genes downstream of BRCA1, mutant cells can bypass cell-cycle checkpoints and apoptosis, which results in continued proliferation and the development of breast cancer (Khanna and Jackson, 2001) .
Several studies have made progress towards defining the nature of additional mutations that are required for malignant transformation of BRCA1-deficient cells. For instance, comparative genomic hybridization (CGH) of breast tumors from BRCA1 mutation carriers revealed a distinct pattern of genomic imbalances, providing evidence that genomic imbalances differ from those observed in sporadic breast cancers . Detailed karyotype analysis of a breast cancer cell line homozygous for a BRCA1 mutation revealed multiple chromosomal aberrations, including a high degree of aneuploidy, loss of wild-type p53, acquired homozygous deletion of the PTEN tumor suppressor gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer (Tomlinson et al., 1998) .
Mouse models of human cancers are enormously important tools to dissect genetic pathways of tumorigenesis. Several groups have therefore attempted to recapitulate mammary gland tumorigenesis in mice deficient for Brca1 (Deng and Brodie, 2001 ). However, homozygous loss of Brca1 results in embryonic lethality at day E5.5 -18.5 (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) . Mouse embryonic fibroblast cells (MEFs), which carry a targeted deletion in exon 11 of Brca1, exhibit chromosome instability, amplification of functional centrosomes, and are defective in the G 2 -M checkpoint (Xu et al., 1999b) . However, the conditional elimination of Brca1 in the mammary gland epithelium using a Cre-loxP approach results in blunted ductal morphogenesis and tumor formation after approximately 1 year (Xu et al., 1999a) . The long latency suggests that additional genetic changes are necessary for tumorigenesis. For instance, loss of p53 accelerated the formation of mammary tumors (Xu et al., 1999a) . To characterize the genomic instability observed in these tumors, to establish a comparative map of chromosomal imbalances and to contribute to the validation of this mouse model of breast cancer, we have mapped DNA gains and losses and characterized chromosomal aberrations using comparative genomic hybridization (CGH) and spectral karyotyping (SKY). As a potential cause for chromosomal aneuploidy, the integrity of centrosomes was assessed by immunocytochemistry and electron microscopy. Additionally, as breast cancers in BRCA1 carriers typically contain either a p53 mutation and/or p53 protein accumulation we analysed several of the tumors for presence of the p53 gene and protein. The results reveal striking similarities between this mouse model and human breast carcinomas precipitated by mutations in the BRCA1 tumor suppressor gene.
Results

CGH of primary Brca1-deficient tumors reveals a pattern of chromosomal gains and losses similar to human breast cancer
To analyse chromosomal copy number changes in Brca1-deficient tumors, we performed CGH using genomic DNA from 11 Brca1 conditional mutant mammary gland tumors (Brca1 Ko/Co Wap-Cre or MMTV-Cre), designated brt-1 through brt-11, and from four Brca1 conditional tumors in a p53 mutant background (Brca1 Ko/Co Wap-CreTrp53 +/7 ), designated pbrt-1 through pbrt-4. A summary of chromosomal copy number changes is presented in Figure 1 . Each chromosome was involved in at least one gain or loss, but the distribution of genomic imbalances was nonrandom, which allows for a comparison with chromosomal copy number changes in human breast cancer. The number of chromosome copy alterations ranged from two to 21 per tumor, and the average number of copy alterations (ANCA, Ried et al., 1999) amounts to 8.1 per tumor. We did not observe significantly different ANCA values for the Brca1 tumors in a p53 +/7 background (ANCA=7.25) compared to the Brca1 mutant alone, suggesting that there was no increase in chromosomal instability. The most consistent changes in both groups were gain of distal chromosome 11, partial gain of chromosome 15, loss of distal chromosome 14 and chromosome 4, and gain of the X-chromosome.
Nine of 15 tumors (brt-2, -4, -5, -6, -9, -10, -11, and pbrt-1 and -4) exhibited a gain of distal chromosome 11 (Figure 1 ). The common portion gained centered on 11D-E, a region that is orthologous to human chromosome 17q11-qter. Four of the tumors (brt-5, -9, -10 and pbrt-1) also exhibited a copy number loss of proximal chromosome 11 (11A-B), a region orthologous to human 17p that may include the p53 gene (which maps to 11B2-C).
In eight of the tumors (brt-1, -2, -5, -6, -8, -10, pbrt-1, -2) we observed whole or partial gain of chromosome 15 centering on 15D2-D3 (orthologous to human chromosome 8q24), the map location of the c-Myc gene. Even in a tumor in which the entire chromosome 15 was gained (pbrt-2), band 15D2-D3 was relatively amplified (Figure 1) .
Six of the tumors (brt-4, -5, -6, -7, -9, -10) exhibited copy number loss of whole or partial chromosome 14, including 14D3, the map location of Rb1. Other copy number changes included loss of whole or distal chromosome 4, gain of the X-chromosome, and loss of whole or partial chromosome 12.
As the CGH results indicated an accumulation of genetic defects in the tumor cells, we wished to determine if the observed aberrations would remain stable in cells at late passage. Tumor brt-5 was expanded to passage 31 and CGH was applied to compare to results from the primary tumor material. The cultured cells contained nine additional gains and four additional losses of chromosomal material (data not shown). Moreover, the amplifications that were mapped to chromosome 11D-E and chromosome 15D exhibited higher-level copy number increases relative to the primary tumor. Despite this chromosomal instability in dividing cells, the majority of the aberrations found in the primary tumor is continuously selected for and therefore maintained even during ongoing cell culture. Clearly the selective pressures are different for cells growing in culture than for cells dividing in the context of mammary tissue. However, we can surmise that the consistent aberrations seen at the genomic level are the ones that give the cells a growth advantage, and additional genetic changes necessary for growth in tissue culture may not be visible at the genomic level. This is consistent with results obtained from human epithelial cancer cell lines (Ghadimi et al., 1999) .
SKY analysis of Brca1-deficient tumors shows gross chromosomal instability yet recurrent aberrations
In order to examine the chromosomal mechanisms that result in the recurring copy number changes found in the Brca1
Ko/Co mammary tumors, we applied SKY to tumor metaphase chromosomes. Although we were unable to obtain metaphases from primary cultures of every tumor, we obtained karyotype data from passage 0 or 1 from tumors brt-1, -2, -5, -9 and -10, and Brca1
Ko/Co Trp53 +/7 tumor pbrt-1 and pbrt-3 (Table  1 ). In only one case (brt-5) was SKY not performed until a later passage (p31).
Every tumor displayed structural aberrations and numerical chromosomal aberrations, but different degrees of multiclonality. Only two of the tumors (brt-1 and -2) were largely clonal in origin; all others had individual 'marker' chromosomes that were present in many or most of the cells accompanied by numerous additional sporadic aberrations in individual cells, indicative of a high degree of chromosomal instability. Chromosome and chromatid breaks were observed in many cases, and in some instances chromosomes appeared to be captured in the process of rearranging (Figure 2 ).
Tumor brt-2 serves as a representative example of SKY analysis of a primary culture. The karyotype included structural aberrations such as insertions, deletions, dicentric chromosomes, and chromatid breakage (Figure 2 ). Despite this considerable degree Recurring genomic imbalances in Brca1-deficient mice Z Weaver et al of chromosome instability, the population of cells was mainly clonal and the CGH profile is in good agreement with the aberrations detected by SKY. For example, chromosome 9 material containing the centromere is found in a dicentric chromosome in which a portion of chromosome 8 is inserted, in a translocation with chromosome 6, and in a chromosome 9, which has an insertion of chromosome 6 material ( Figure 2) . Accordingly, the CGH profile for this tumor (brt-2) shows a gain of the proximal region of chromosome 9 (Figure 1) . Similarly, SKY indicates that there is an extra copy of chromosome 15 relative to the ploidy of the cell (Figure 2) , and the CGH profile shows a gain of chromosome 15 (Figure 1 ). The representative metaphase in Figure 2 does not contain the extra copies of chromosome 11 material seen in other cells of this tumor. However, FISH with chromosome painting probes indicated additional small fragments containing chromosome 11 (Table 1) . Moreover, the metaphase does show evidence for chromosome 11 instability: one copy of the chromosome is in the process of re-arranging with chromosome 13 (Figure 2a, b) .
In tumor brt-1, we could compare SKY data from both early and late passages. Although the majority of cells increased in ploidy from 2n to ranging from 3n -4n after 31 passages, the T(7;11) was retained (Table  1) . A whole chromosome paint for chromosome 11 revealed additional copies of a Del(11), which preserved the distal portion of that chromosome including the Erbb2 locus (see FISH results below). Therefore even a primary tumor without a chromosome 11 gain ( Figure 1 ) eventually selected for the amplification of distal chromosome 11 when passaged in culture.
Two tumors, pbrt-1 and pbrt-3, that arose in Brca1
Ko/Co Wap-CreTrp53 +/7 mice were analysed by SKY (Table 1) . Although these tumors both contained Trp53 appears to be nd at T(7;11) breakpoint brt-1(p31) 53n-4n4 T(7;11) 3 -4 copies del(11) Erbb2 telomeric to the breakpoint on chr11 brt-2 3n Del(1), T(3;12), T(6;9;8), 1 -3 normal 11, Del(11), Trp53 on normal 11, Erbb2 on normal 11, T(8;19), clonal Dic(ls(8;9)), T(9;6), Del(11), 1 -3 copies of a translocation not on translocated not on translocated T(11;13), T(13;11), Del(X) of *1 band of 11 to either cent pieces pieces or tel or partner chrom (too small to see by SKY) brt-3 6n nd 3 T(11D-E:?), 3 Del(11), nd no Erbb2 on T(11;?), 4-7 T(?;11) Del(11) piece has Erbb2, piece of 11 in T(?;11) has Erbb2 brt-5(p0) 3n nd nd nd nd brt-5(p31) 3n T(6;13), T(7;13), T(8;19), 3 normal chr 11; Trp53 on normal 11 Erbb2 on normal 11 T(9;18), Del(11), T(13;16) 1 -3 copies of a Del(11) not on Del(11) Erbb2 signal on Del(11) T(13;7), T(14;12), T(14;19), i.e., Del(11)=Del(11B-C) T(16;2) brt-6 clone a: 3n clone a: 2 normal 11, 2 Del(11) nd Erbb2 on normal 11 clone b: 4n clone b: 4 normal 11, Del(11) has Erbb2 brt-9 53n4 T(1;2) x2, T(2;1) x2, Del(3) x2, clone a: 2 normal 11, 2 Del(11) nd clone a: Erbb2 on normal 11 57-67 chr R(4;X), D_I(9) x2, Del(11) x2 clone b: 1 normal 11, 2 Del(11), Erbb2 on Del(11), i.e. interstitial del clone b: Erbb2 on normal 11 Erbb2 on Del(11) Erbb2 on T(?;11) no Erbb2 on T(11;?) brt-10 clone a: 6n Del(4), T(6;11), T(11;6?), clone a: 4 normal 11, Trp53 on normal 11 clone a: Erbb2 on 1 normal 11 clone b: 3n Del (11)63 2 Del(11), 4 T(?;11) in both clone a and 3 'normal' 11 have no Erbb2 clone b: 1 normal 11, clone b not on signal, 2 Del(11), 2 T(?,11), deleted or no Erbb2 on 2 Del(11), 1 ls(11;?) translocated pieces Erbb2 signal on 4 T(?;11), clone b: Erbb2 signal on 2 T(?;11), Erbb2 signal on ls(11;?) no Erbb2 on 'normal' 11 no Erbb2 on Del(11) pbrt-1 53n-6n4 Del(4), T(6;11), Del(11) nd nd nd 68-127 chr pbrt-3 3n Rb(2.3)62, T(15;8), nd nd nd T(18;3), T(X;18) a Brt-1 and brt-5 were analysed at passage 0 and passage 31. b Ploidy was determined using the median copy # for each chromosome. c Recurrent aberrations were defined as present in 2 or more metaphases, nd, not determined. d A probe for the entire sequence of chr 11 was used to confirm aberrations and copy #. '?' indicates that the partner chromosome was not identified in this experiment.
e A probe for the Trp53 gene was cohybridized with the chromosome 11 paint probe. f A probe for the Erbb2 gene was cohybridized with the chromosome 11 paint probe
Recurring genomic imbalances in Brca1-deficient mice Z Weaver et al chromosomal aberrations that were present in more than one cell, the degree of chromosomal instability in both made it difficult to reconcile all structural aberrations with the gains and losses seen by CGH (Figure 1 ). Pbrt-1 had an average of six unique structural aberrations per metaphase cell, and pbrt-3 had an average of four unique aberrations. This is different from tumor brt-2, described above, which had multiple aberrations that were present in every cell. Despite this degree of instability, pbrt-1 displayed a gain of distal chromosome 11, as found in the majority of the Brca1-deficient tumors by CGH and SKY (Table 1) . A small deleted chromosome 11 is present in several copies in most of the cells (Table 1) . As it is found in both triploid and tetraploid cells from pbrt-1, it is likely that the acquisition of the Del(11) preceded the tetrapolidization of the genome and was therefore an early event in tumorigenesis. The detailed karyotype description of the cell lines can be retrieved from the database at: www.ncbi.nlm.nih.gov/sky/skyweb.cgi FISH analysis indicates that gain of distal chromosome 11 occurs by several mechanisms CGH and SKY analysis of the Brca1 conditional mammary tumors indicated that chromosome 11 was frequently involved in structural aberrations which resulted in copy number decreases for proximal 11 and increases for the distal portion of this chromosome. To further elucidate the region of gain, loss, or rearrangement, we combined whole chromosome painting with gene-specific FISH probes for p53 and/or Erbb2. Gain of Erbb2 (and potentially other breast cancer-specific oncogenes on distal mouse chromosome 11) and the simultaneous deletion of p53 are accomplished via complex chromosomal rearrangements. The results (shown in Figure 3 and described in Table 1 ), corresponded well with the CGH data. In each case we confirmed the gain of the distal chromosome 11. For example, tumor brt-9 appeared to have a copy number gain of chromosome 11 that included the Erbb2 gene, which maps to 11D (Figures 1 and 3 ). SKY and whole chromosome painting combined with the Erbb2 probe showed that brt-9 has two clones, both of which exhibit two copies of a Del(11) in addition to at least one normal copy (Table 1) . Clone b contains in addition two translocations involving the proximal and distal portions of chromosome 11, respectively (Table 1) . Erbb2 is present on each Del(11) in both clones, indicating that this aberrant chromosome is derived from an interstitial deletion of bands B -C. Erbb2 is also present on the distal translocated portion of chromosome 11 in clone b (Figure 3 ) indicating that the breakpoint is proximal to Erbb2 in this case. Similarly, the gain of 11D-E observed by CGH in tumor brt-5 is due to 1 -3 extra copies of an aberrant chromosome 11 with an interstitial deletion of bands B -C (Table 1) . Conversely, tumour brt-2 showed a gain of chromosome 11 by CGH that appeared to be distal to the , and the full karyotype with display colors on the left of the spectrally-classified chromosomes in (c). White arrows indicate the aberrant chromosome 9 structures, and the arrowhead indicates chromosomes 11 and 13 in the process of rearranging, as described in the text. The complete karyotype of this tumor is 56,XXXX, Del(1)x2, Del(2)x2, Del(3), T(3;12), T(6;9;8)x2, Is(6;9), Dic(Is(8;9)), T(9;6), Del(13), Dic(16;2), T(16;19), Del(X)x2, +1, +6, +15, +16, 74, 75, 77, 78, 710, 711, 712, 714, 717, 719 Erbb2 gene locus, encompassing band 11E only (Figures 1 and 3) . FISH analysis revealed that indeed there are extra copies of a small deleted chromosome 11 relative to the ploidy (triploid) of the tumor (Table  1) . We could show that this Del(11) did not contain the Erbb2 locus by FISH analysis (Figure 3) . By CGH, the profile for chromosome 11 in brt-10 appeared similar to that of brt-2 in that the gain of the distal region was limited to 11E (Figures 1 and 3) . However, in this case the FISH analysis revealed (in both of the two clones identified) that Erbb2 is not gained relative to the copy number of chromosome 11, because it is located on the portion of chromosome 11 that is deleted by way of a structural aberration. For example, in clone b, which is triploid, there is one copy of a 'normal' chromosome 11, 2 Del(11), two translocations involving the distal region of 11, and one insertion of a portion of chromosome 11 into another chromosome (Table 1) . Erbb2 is present on the translocated pieces of chromosome 11 and on the small insertion, but not on the Del(11), and not on the chromosome 11 that appears to be of normal size by painting, but which must have a small deletion in the Erbb2 band region (Figure 3) . Therefore, the mechanism for the gain of distal chromosome 11 does not always involve gain of Erbb2, but always include the region directly distal to that gene.
To confirm that the structural aberrations were distal to the location of the tumor suppressor gene p53 (11B2-C) we analysed four tumors with a FISH probe for p53. Three of these tumors (brt-2, -5 and -10) showed gain of chromosome 11 by CGH, and one did not (brt-1). The results indicate that p53 was excluded from the copy number increases of distal chromosome 11 as it was observed only on the normal copy of the chromosome in these tumors and not on any of the deleted or translocated portions (Table 1) . p53 was also present on the normal-size chromosome in brt-10 that was deleted for Erbb2. Tumor brt-1 showed no copy number change of chromosome 11 by CGH, but SKY analysis revealed a reciprocal T(7;11) in every cell (Table 1) . By FISH analysis, we confirmed that p53 is likely to be at the breakpoint of the clonal translocation observed by SKY (Figure 3) because the probe signals are on either side of the translocated chromosome 11 and also differ in size. This evidence supports our previous results, which had indicated that the p53 transcript size was abnormal in tumor brt-1 (Xu et al., 1999a) . Although p53 inactivation seems to occur via chromosome translocation in this tumor, additional mechanisms other than chromosomal translocations may be responsible for p53 mutation in Brca1-deficient mammary tumors (Xu et al., 1999a; and see below) .
Western blot analysis reveals aberrant p53 expression in some tumors
To determine whether the expression of p53 was changed even in cases where the gene did not appear to be deleted or rearranged by FISH analysis, we prepared protein extractions from several tumors, both Brca1
Ko/Co Wap-Cre and Brca1 Ko/Co Wap-CreTrp53 +/7 from which it had been possible to maintain the cells in culture for 20 -30 passages (Figure 4 ). Brt-1 produced no detectable protein product. Similarly, no p53 product was observed from the brt-9 or pbrt-3 cells. Although the a-tubulin control indicates that less protein may have been loaded in lanes 1, 3 and 4, we have performed the experiment several times, also using an antibody for actin detection as yet another control, and have never detected protein in brt-1, pbrt-3 or brt-9 (data not shown). As described previously, brt-1 displayed a rearranged p53 gene by FISH analysis (Table 1) and by Northern blot analysis of its transcript (Xu et al, 1999a) . Although it appears that no protein product is produced, we cannot rule out the possibility of a mutant (fusion) protein, which the p53 Recurring genomic imbalances in Brca1-deficient mice Z Weaver et al antibody does not recognize. Chromosome rearrangements are also a likely cause of p53 loss in brt-9: this tumor displayed a gain of chromosome 11 distal to p53 by CGH, and SKY revealed the gain was due to translocations and interstitial deletions of chromosome 11. Brt-5 appeared to express a mutant version of p53 greater than 64 kD. This tumor exhibited a deleted chromosome 11, which results in the loss of the p53 gene (Table 1 ). The mutant p53 protein must be the result of a gene rearrangement that was too small to visualize by cytogenetic techniques. Interestingly, two cell lines (brt-10 and pbrt-1) representing the p53 +/+ and p53
genetic backgrounds, respectively, appeared to express p53 protein products of normal size, although p53 is expressed at a higher level in brt-10 relative to pbrt-1 and to the positive control.
Centrosome abnormalities and aberrant mitoses likely contribute to chromosome instability
We have shown previously that MEFs carrying a targeted deletion in the Brca1 gene contain multiple functional centrosomes, which result in multipolar and catastrophic mitoses (Xu et al., 1999b) . To examine whether the mammary tumor cells lacking Brca1 exhibit a similar phenotype, we stained tumor cells from four tumors (brt-1, -2, -9, -10) with an antibody against the g-tubulin component of the centrosome. We found that 25% of tumor cells contained an abnormal number of three or more centrosomes. The simultaneous stain for DNA clearly showed that these supernumerary centrosomes caused unequal segregation of chromosomes and multipolar mitoses ( Figure  5a,b) . In addition to its ability to nucleate microtubules, another criterion for an intact centrosome is that it should contain two centrioles. To examine the supernumerary centrosomes in greater detail, we performed electron microscopy on cells from tumor brt-10 in which the centrosomes had been detected earlier using a glutaraldehyde-stable antibody against g-tubulin. After relocation of the fluorescent signals and acquisition of images from multiple image planes, we could show that each centrosome detected by the anti-g-tubulin antibody contained normal centrioles (Figure 5c,d) . The centrioles in the cells with additional centrosomes did not appear different than those in the cells with only two centrosomes (data not shown).
Discussion
The conditionally mutant Brca1 mouse was created as a model for inherited human breast cancer (Xu et al., 1999a) . Previous studies have shown that these mice develop mammary tumors after a long latency, which is decreased in a p53 mutant background. We have now performed molecular cytogenetic analysis on a series of mammary tumors from these mice in order to assess whether the strictly conserved distribution of genomic imbalances observed in human breast cancers is The pair on the top left is the most clearly visible; note that this is a cross-section through the cell and the visualization of all pairs would require a series of images maintained in this mouse model. This would support its use as a tool to study breast tumorigenesis. We found that all tumors exhibit chromosome instability as evidenced by structural chromosomal aberrations and aneuploidy, yet that they display a pattern of chromosomal gain and loss that is similar to the pattern observed in human breast carcinomas, and in particular to BRCA1-associated tumors. Although Brca1 mutant embryonic cells exhibit random chromosome aberrations and early lethality, deficiency of Brca1 in the mammary gland allows for the selection of specific genetic changes and subsequent malignant transformation.
Comparative maps of the human and murine genome allowed us to compare the distribution of genomic imbalances between human and mouse. For example, the commonly gained region on chromosome 11 centered on bands 11D-E, a region that is orthologous to human chromosome 17q11-qter, which is frequently amplified in human breast carcinomas (Bieche and Lidereau, 1995; Ried et al., 1995; Barlund et al., 1997) . Of note, the amplicon on chromosome band 17q23, associated with poor prognosis in human cancers, was recently shown to have a limited number of highly expressed genes that may contribute to the more aggressive phenotype (Monni et al., 2001) . Another analogy extends to the c-Myc oncogene, another common target for amplification in human breast cancer, both in sporadic and BRCA1-mutation associated tumors (Nass and Dickson, 1997). As shown in our analysis, the locus containing the c-Myc gene in the mouse (15D2-D3) is subject to recurring copy number increase in the Brca1-deficient mouse tumors. Interestingly, analysis of mouse mammary tumors resulting from overexpression of a c-Myc transgene also revealed a copy number gain of the distal region of chromosome 11 .
Although the chromosome regions appearing as gains by CGH are large, recent studies in which genomic gains and losses have been compared to tumor gene expression profiles have shown that in fact very few genes are both amplified and overexpressed in these regions (Phillips et al., 2001; Platzer et al., 2002) . The comparative mapping of genomic imbalances in human and murine tumors supports this view: despite a frequent gain of the entire long arm of chromosome 8 in human breast carcinomas, not all chromosomal segments of the mouse genome that are orthologous to human chromosome 8 are present in increased copy numbers. In fact, only the segments on murine chromosome 15 are amplified. This finding suggests that indeed oncogenes that reside on human chromosome 8 segments that are present on mouse chromosome 15 are required for tumorigenesis. The c-Myc oncogene is obviously a likely candidate.
Our results from the mouse Brca1 model can also be specifically compared to the distribution of chromosome gain and loss in human breast cancers from BRCA1 carriers. Tirkkonen et al. (1997) found recurring copy number increases on chromosome band 17q22-24 and chromosome arms 8q and 1q. The 8q gain is likely due to c-Myc amplification as seen in the Brca1-deficient mice, and it is reasonable to suspect that the crucial gene(s) amplified on 17q are homologues of those on mouse 11D-E. Similarly, chromosome 13q exhibited loss in a majority of the BRCA1 cancers, and the region of mouse chromosome 14 commonly lost in the Brca1-deficient tumors is homologous to 13q. The most frequent loss found in the human BRCA1 breast cancers was mapped to chromosome 5q. Several mouse chromosomes have homology to 5q so a direct comparison is difficult; however it is interesting that the common region of mouse chromosome 11 loss in five tumors (band 11A5) is orthologous to human 5q35 and one can speculate that this chromosome band is the target for loss in human cancers. Progress in the mouse genome sequencing efforts and the development of precise maps of homology will continue to facilitate efforts for comparative molecular cytogenetic studies.
The genomic instability present in these tumors was best visualized by SKY. By analysing multiple metaphases for each tumor it became clear that new structural aberrations are continuously arising as the cells are dividing. Every tumor displayed structural aberrations, numerical chromosomal abberations and multiple clones. Even though the ploidy varied within some tumors, the recurrent marker chromosomes were replicated along with the chromosomal complement, and therefore resulted in overall copy number changes. Analysis of the specific chromosome regions involved in the most recurrent rearrangements enables us to elucidate the mechanism behind the gains and losses found in the CGH profiles.
In the case of the distal region of chromosome 11, SKY revealed a Del(11) in several tumors, and we used gene-specific probes to show that an interstitial deletion occurred in that chromosome. Whole chromosome painting indicated that the region of chromosome 11 that shows a copy number increase by CGH is gained relative to the ploidy of individual tumor cells, and gene-specific FISH showed that the region does not always include the Erbb2 gene, but always includes the band distal to that gene. Although the Erbb2 gene is amplified in many somatic breast carcinomas, evidence suggests that this locus is not commonly gained or overexpressed in BRCA1-related breast or ovarian cancers Rhei et al., 1998; Vaziri et al., 2001) . Studies that correlate gene amplification with gene overexpression point to another gene on 17q23, orthologous to mouse 11D-E (Wu et al., 2000; Monni et al., 2001) . Therefore this model could be used to confirm the relevance of candidate genes in human BRCA1-related breast cancer.
Taken together, the CGH and SKY data show that the average number of chromosomal aberrations in these tumors is similar to the number observed in human cancers. Aneuploid breast carcinomas show an ANCA of 6.8-12 . By CGH we observed an ANCA of 8.1 for the Brca1-deficient mammary tumors. This number is higher than in murine tumors induced by overexpression of an oncogene, such as in MMTV-c-myc (ANCA=5.5) or Erbb2 (ANCA-2.7) transgenics Montagna et al., 2002) . Conditional knockout of the Brca1 tumor suppressor gene may more closely model familial breast cancer as the second allele is only mutated as the mice reach maturity (Xu et al., 1999a) . During the long latency, additional genetic changes occur which eventually leads to tumor formation. In the transgenic mice, tumor induction via a strong oncogenic stimulus may circumvent the need for the acquisition of tumor-specific patterns of chromosomal aneuploidies. With the recent success of the Cre-loxP technology, it may become easier to create conditional tumor suppressor gene deletion models that more closely reflect the nature of multi-step carcinogenesis that we observe in human epithelial cancers.
The development of mammary tumors conditionally deleted for Brca1 is accelerated in a p53 +/7 background (Xu et al., 1999a) . It has also been found that haploid loss of p53 can completely rescue the embryonic lethality caused by the Brac1 D11/D11 mutation by way of reduced apoptotic response and impaired G1-S checkpoint control (Xu et al., 2001) . Clearly, interactions between p53 and Brca1 are important for the maintenance of genomic stability. BRCA1-related familial breast cancers are known to contain a higher frequency of TP53 alterations than sporadic breast and ovarian tumors. Null mutations, as well as mutations that result in the accumulation of p53, have been found. However, although TP53 mutations clearly occur more often in BRCA1-associated tumors than in sporadic breast cancers, no absolute requirement for TP53 mutation has been proven . Three of the murine tumors analysed in this study produced no detectable p53 protein, which was in at least one case (brt-1) due to rearrangement of the gene. Still, we did detect p53 protein of the expected size in two tumors, brt-10 and pbrt-3 (which were germline wild-type and heterozygous mutant for p53, respectively). We cannot rule out that these proteins contain deregulating point mutations, as the p53 protein was found to have decreased stability even in Brca1 ko/ko p53 +/+ thymocytes (Xu et al, 1999a) . During the long latency to tumor formation the severe genomic instability in these tumors may also cause the disruption of other genes in the p53 pathway, for instance p21. However, these tumors might provide evidence that tumorigenesis can occur even in the presence of wild-type p53.
We have previously shown that fibroblasts from Brca1 null embryos exhibit abnormal numbers of centrosomes, aneuploidy, and are deficient in the G2-M checkpoint. Dual immunostaining for g-and atubulin also revealed that the amplified centrosomes could nucleate tubulin and organize spindle poles (Xu et al., 1999b ). Now we find that Brca1-deficient mammary tumor cells maintain this centrosome amplification. By electron microscopy, the centrioles appear structurally normal, unlike those in aneuploid colorectal cancer cell lines, where the absence of colocalization of g-tubulin positive spots with centrioles correlate with the presence of non-functional centrosomes and the absence of multipolar mitoses (M Difilippantonio et al, submitted). We have shown earlier that amplified centrosomes are already present in the earliest Brca1 7/7 embryonic cell divisions (Xu et al., 1999b) . This suggests that the segregation defects associated with supernumerary functional centrosomes in this mouse model of breast cancer may indeed contribute to the generation of aneuploidy. BRCA1 colocalizes with the centrosome during mitosis and coimmunoprecipitates with g-tubulin, a centrosomal component essential for nucleation of microtubules (Hsu and White, 1998) . The absence of BRCA1 could therefore directly trigger the emergence of centrosome abnormalities.
We conclude that this comprehensive characterization of chromosomal and genetic defects in mammary gland adenocarcinomas in mice conditionally deficient for Brca1 has established firm evidence of the similarity with human breast cancers. This extends from the identification of a pattern of genomic imbalances conserved across species from mice to men, to the confirmation of loss of p53 in BRCA1-associated tumorigenesis, and to the description of multiple functional centrosomes that induce aneuploidy. Such analyses validate murine experimental tumor sysems as germane models for human cancer.
Materials and methods
Cell culture
For short-term culture, the tumors were minced with scalpel blades, digested in 0.5 mg/ml collagenase type III (Invitrogen, Carlsbad, CA, USA) in modified IMEM medium (Invitrogen) for 5 h to overnight. The cells were then washed twice and resuspended in modified IMEM+2.5% FBS. Seven of the tumors were harvested for metaphase chromosome preparation (see below) at 48 -72 h. For long-term culture, cells were maintained in modified IMEM+2.5% FBS and cleared of contaminating fibroblasts by differential trypsinization.
SKY and FISH
Metaphase chromosomes for SKY were prepared from tumor cells at passage 0 -2. Cells in culture were incubated for 5 h in 0.02 mg/ml Colcemid (Invitrogen), 30 mg/ml bromodeoxyuridine (Sigma, St. Louis, MO, USA) and 0.15 mg/ml fluorodeoxyuridine (Sigma). The cells were lysed in hypotonic solution (0.06 M KCl) and the chromsomes were fixed in methanol:acetic acid (3:1). Spectral karyotyping was performed as described previously (Liyanage et al., 1996; Weaver et al., 1999) . For each tumor, at least five metaphases were analysed.
Mouse p53 and Erbb2 BAC clones were obtained from a Genome Systems (St Louis, MO, USA) library screen using gene-specific primers. Both the Erbb2 and the p53 BACs were labeled by nick-translation with Spectrum Orange dUTP (Vysis, Downers Grove, IL, USA). Chromosome 11 was similarly labeled directly with dUTP-Cy5 or indirectly with biotin-16-dUTP (Roche Biomolecular, Indianapolis, IN, USA) and detected with FITC conjugated to avidin (Vector Laboratories, Burlingame, CA, USA). The SKY and CGH
